Class / Patent application number | Description | Number of patent applications / Date published |
546097000 | Two of the cyclos share at least three ring carbons (e.g., benzomorphans, etc.) | 8 |
20090062546 | Dolasetron trifluoroacetate, polymorphs of dolasetron trifluoroacetate and process for preparation thereof - Provided are crystalline forms of dolasetron trifluoroacetate, methods for their preparation, and their use in preparing dolasetron mesylate. | 03-05-2009 |
20090247754 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF - The present invention is related to the synthesis of huperzine A. The synthesis includes a variety of process steps that increase productivity, reduce safety concerns, and allow for increasing production of compounds of desired optical isomer. The inventive methods may encompass a single improved reaction step that may be incorporated into a known reaction process for synthesizing huperzine A or a derivative thereof to improve the overall reaction. The inventive methods also encompass complete synthesis methods for preparing huperzine A or a derivative thereof. | 10-01-2009 |
20100010225 | ISOQUINUCLIDINE DERIVATIVE AND METHOD FOR MANUFACTURING 1-CYCLOHEXENE-1-CARBOXYLIC ACID DERIVATIVE USING THE SAME - The present invention provides an isoquinuclidine derivative which can be used to easily synthesize oseltamivir or an analog thereof. In particular, the present invention provides an isoquinuclidine derivative represented by the following formula (1) or an enantiomer thereof: | 01-14-2010 |
20100184986 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE - Organocatalysts, particularly proline sulfonamide organocatalysts, having a first general formula as follows are disclosed. | 07-22-2010 |
20130317226 | INHIBITORS OF THE INTERACTION OF THE SIGMA-1 RECEPTOR WITH hERG FOR USE IN THE TREATMENT OF CANCER - The present invention relates to the use of the Sigma-1 receptor (Sig1R) in the context of the post-transcriptional regulation of the membrane expression of ion channels. | 11-28-2013 |
20150141650 | DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF - The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions. | 05-21-2015 |
20160096808 | METHODS OF RESOLVING RACEMIC MIXTURE TO OBTAIN (-)-HUPERZINE A - A method of resolving a racemic mixture of (±)-Huperzine A to (−)-Huperzine A includes: separating the (−)-Huperzine A from the racemic mixture of (±)-Huperzine A by chiral high performance liquid chromatography (HPLC), the chiral HPLC being performed utilizing a mobile phase including a solution including an alcohol and one selected from dichloromethane, trichloromethane, and a mixture thereof, and the chiral HPLC being performed utilizing a chiral stationary phase including a polysaccharide derivative. | 04-07-2016 |
20160159745 | PREPARATION OF (-)-HUPERZINE A - The present invention relates to a method for preparing (−)-huperzine A. The method involves: allowing a mixture of (±)-huperzine A obtained from chemical synthesis and a chiral acid to form (±)-huperzine A chiral acid salt under suitable conditions; recrystallizing the chiral acid salt from an organic solvent and basifying with an alkali to obtain optically pure (−)-huperzine A. The method is convenient to operate and suitable for industrial production. The chemical purity and optical purity of (−)-huperzine A obtained by the method are each greater than 99.5%, satisfying the requirement for raw pharmaceutical purity in the pharmaceutical industry. | 06-09-2016 |